Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging
Tóm tắt
The purpose of this study was to carefully analyse the therapeutic benefit of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) and cardiomyopathy (ATTRwt-CM) after one year of therapy based on serial multi-parametric cardiovascular magnetic resonance (CMR) imaging. Non-sponsored data based on multi-parametric CMR regarding the effect of tafamidis on the cardiac phenotype of patients with ATTRwt-CM are not available so far. The present study comprised N = 40 patients with ATTRwt-CM who underwent two serial multi-parametric CMR studies within a follow-up period of 12 ± 3 months. Baseline (BL) clinical parameters, serum biomarkers and CMR findings were compared to follow-up (FU) values in patients treated “with” tafamidis 61 mg daily (n = 20, group A) and those “without” tafamidis therapy (n = 20, group B). CMR studies were performed on a 1.5-T system and comprised cine-imaging, pre- and post-contrast T1-mapping and additional calculation of extracellular volume fraction (ECV) values. While left ventricular ejection fraction (LV-EF), left ventricular mass index (LVMi), left ventricular wall thickness (LVWT), native T1- and ECV values remained unchanged in the tafamidis group A, a slight reduction in LV-EF (p = 0.003) as well as a subtle increase in LVMi (p = 0.034), in LVWT (p = 0.001), in native T1- (p = 0.038) and ECV-values (p = 0.017) were observed in the untreated group B. Serum NT-proBNP levels showed an overall increase in both groups, however, with the untreated group B showing a relatively higher increase compared to the treated group A. Assessment of NYHA class did not result in significant intra-group differences when BL were compared with FU, but a trend to improvement in the treated group A compared to a worsening trend in the untreated group B (∆p = 0.005). As expected, tafamidis does not improve cardiac phenotype in patients with ATTRwt-CM after one year of therapy. However, tafamidis seems to slow down cardiac disease progression in patients with ATTRwt-CM compared to those without tafamidis therapy based on multi-parametric CMR data already after one year of therapy.
Tài liệu tham khảo
Palladini G, Merlini G (2016) What is new in diagnosis and management of light chain amyloidosis? Blood 128(2):159–168
Grogan M, Scott CG, Kyle RA et al (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68(10):1014–1020
Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126(10):1286–1300
Gertz MA, Benson MD, Dyck PJ et al (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66(21):2451–2466
Maurer MS, Kristen A (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007–1016
Adams DB, Kristen A (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11–21. https://doi.org/10.1056/NEJMoa1716153
Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31
Florian A, Bietenbeck M, Chatzantonis G, Hüsing-Kabar A, Schmidt H, Yilmaz A (2020) Regression of cardiac amyloid load documented by cardiovascular magnetic resonance in a patient with hereditary amyloidosis. Clin Res Cardiol Off J Ger Card Soc 109(7):949–956
Fontana M, Martinez-Naharro A, Chacko L et al (2021) Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging 14(1):189–199
Kazi DS, Bellows BK, Baron SJ et al (2020) Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation 141(15):1214–1224
Maceira AM, Joshi J, Prasad SK et al (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111(2):186–193
Fontana M, Banypersad SM, Treibel TA et al (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7(2):157–165
Amzulescu MS, de Craene M, Langet H et al (2019) Myocardial strain imaging: review of general principles, validation, and sources of discrepancies. Eur Heart J Cardiovasc Imaging 20(6):605–619
Yilmaz A, Bauersachs J, Bengel F et al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol Off J Ger Card Soc 110(4):479–506
Chatzantonis G, Bietenbeck M, Elsanhoury A et al (2021) Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol Off J Ger Card Soc 110(4):555–568
Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E (2013) Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 15:91
Korthals D, Chatzantonis G, Bietenbeck M, Meier C, Stalling P, Yilmaz A (2021) CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis. Sci Rep 11(1):15521
Bistoquet A, Oshinski J, Skrinjar O (2007) Left ventricular deformation recovery from cine MRI using an incompressible model. IEEE Trans Med Imaging 26(9):1136–1153
Phelan D, Collier P, Thavendiranathan P et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart (British Cardiac Society) 98(19):1442–1448
Addison D, Slivnick JA, Campbell CM, Vallakati A, Jneid H, Schelbert E (2021) Recent advances and current dilemmas in the diagnosis and management of transthyretin cardiac amyloidosis. J Am Heart Assoc 10(9):e019840
Garcia-Pavia P, Rapezzi C, Adler Y et al (2021) Diagnosis and treatment of cardiac amyloidosis. A position statement of the European society of cardiology working group on myocardial and pericardial diseases. European J Heart Fail 23(4):512–526
Patel RK, Fontana M, Ruberg FL (2021) Cardiac amyloidosis: multimodal imaging of disease activity and response to treatment. Circ Cardiovasc Imaging 14(6):e009025
Gillmore JD, Damy T, Fontana M et al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799–2806